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Abstract
Background: The quality of life in patients receiving chronic hemodialysis is compromised despite of the substantial
achievements in treatments. Quality of life in hemodialysis patients have been shown to be associated with decreased
survival and increased hospitalization. Therefore, it is necessary to incorporate the managements of symptoms and
patient self-perceived well-being as measurements of effective treatments for these patients.
Methods: A survey of symptom distress, quality of sleep and quality of life was performed in 301 maintenance
hemodialysis patients using Dialysis Symptom Index, Short Form-36, and Pittsburgh Quality of Sleep Index table.
Patients were recruited from five hospitals in Guangdong area of China by convenience sampling.
Results: The prevalence of various symptoms in maintenance hemodialysis patients was between 23.3 and 80.4 %.
These patients had compromised sleep and poor quality of life. Moreover, poor quality of sleep and impaired quality
of life were associated with high symptom burden of these patients.
Conclusion: The patients receiving chronic hemodialysis generally have heavy symptom distress, which could
contribute to the disturbed sleep and impaired quality of life of these patients. Measurements of clinical outcomes for
hemodialysis patients should include the management of symptoms and morbidity. The ultimate goal of treatments is
to improve patient self-perceived quality of life.
Keywords: Maintenance hemodialysis, Symptom distress, Quality of life, Quality of sleep
Background
With the increase in the patients with diabetes and
hypertension, the number of patients with end-stage
renal disease (ESDR) grows rapidly worldwide [1, 2].
The survival of hemodialysis patients improved due to
the advancements in treatments [2]. However, compro-
mised quality of life is common in patients on chronic
hemodialysis [3–8]. Notably, reduced life quality was
strongly associated with higher risk of death and
hospitalization in hemodialysis patients [3, 5–7]. Com-
plex factors contribute to a lower quality of life in
hemodialysis patients [6–9]. Among these, poor sleep is
common in patients receiving hemodialysis, and studies
showed that sleep quality predicts quality of life and
mortality risk in haemodialysis patients [9, 10]. Patients
with ESRD who are treated with dialysis may experi-
ence many threats to their social, physical and mental
capacities, both from the symptoms of ESRD, lifestyle
alteration and the treatment-related side-effects on
daily life. Hemodialysis patients did suffer from a series
of physical and emotional symptoms which negatively
affect their physical and mental health. However, the
association between symptom distress and sleep quality
as well as quality of life in maintenance hemodialysis
(MHD) patients in China has not been fully addressed.
Considering that China has the largest population in
the world and there is a rapid growth in the number of
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hemodialysis patients, it is necessary to explore the
symptom burden and its impact on the patient self-
perceived well-being of this population in China. There-
fore, the goal of this study was to investigate the preva-
lence of symptoms as well as the correlation between
symptom distress and quality of life in MHD patients re-
cruited from five dialysis units in southern China. We
hope that the results of the current study would help find
solutions to identify potential interventions to prevent ad-
verse outcomes of ESRD patients and to improve their
clinical outcomes.
In the present study, we used SF-36 questionnaire to
assess the quality of life, the Pittsburgh Seep Quality
Index (PSQI) to evaluate the quality of sleep and the
Dialysis Symptom Index (DSI) to examine the symp-
tom distress in 301 patients from southern China. The
findings of this study provide helpful information for
improving current hemodialysis guidelines, as well as
choosing optimal treatments to control symptoms,




Patients were recruited from the dialysis unit of five hos-
pitals in Guangdong province, including the First and
Second Affiliated Hospitals of Sun Yat-sen University,
Hospital of Dongshang District, People’s Hospital of
Jiangmen Xinhui City and Huiya Hospital of Huizhou
City by convenience sampling. The criteria for recruiting
patients were: (1) Symptoms of patients met the require-
ments for the diagnosis of uremia upon admission to the
hemodialysis center, which include: a) history of chronic
kidney disease; b) symptoms such as nausea, vomiting,
fatigue, anorexia, weight loss, muscle cramps, pruritus
and change in mental status; c) estimated glomerular filtra-
tion rate (eGFR) < 10 ml/(min · 1.73 m2) in patients with
non-diabetic kidney diseases; eGFR < 15 ml/(min · 1.73 m2)
in patients with diabetic kidney disease; (2) Patients should
have received at least 3 months of hemodialysis; (3) At the
time of survey, patients were under stable conditions with-
out any severe comorbidities of heart, brain and lungs,
including chronic or acute heart failure, heart attack, stroke,
respiratory failure, acute or chronic liver failure, cancer and
dementia; (4) Patients were conscious with normal judg-
ment, were able to understand the questionnaire and
willing to participate the survey; (5) Questionnaires were
distributed and explained to patients by trained nurses once
informed consent was obtained.
Survey was performed by patient self-administered
questionnaires. Laboratory tests, quality of life and sleep
were evaluated concurrently with the examination of
symptoms.
1) General information
Patients’ general information included gender, age,
dialysis modules, dialysis frequency and the duration
of dialysis. Results of laboratory tests, including
hemoglobin, red blood cell, hematocrit, serum
phosphorus, product of calcium and phosphorus
and intact parathyroid hormone (iPTH), were also
collected at the time of survey. Kt/V, a way of
measuring dialysis adequacy, was calculated. In this
measurement, K stands for the dialyzer clearance,
the rate at which blood passes through the dialyzer,
expressed in milliliters per minute (mL/min), t stands
for time. Kt represents the volume of fluid completely
cleared of urea during a single treatment. V is the
volume of water that a patient’s body contains.
2) Symptoms
The reliability and validity of the Dialysis Symptom
Index (DSI) to assess symptom distress in
hemodialysis population have been demonstrated
in previous studies [11, 12]. We used the DSI to
evaluate physical and emotional symptoms as well
as their severity. The DSI contains 30 items with
each representing a specific physical or emotional
symptom. The enrolled patients were asked to
report the presence of each symptom at any time
during the previous 7 days by answering “yes” or
“no”. Using a modified five point Likert scale
(0: “not at all bothersome”, 1: “bothers a little bit”,
2: “bothers somewhat”, 3: “bothers quite a bit”
and 4: “bothers very much”), the severity of each
symptom was assessed by asking patients to rate
how much the symptom was bothersome.
3) Quality of Sleep
The Pittsburgh Sleep Quality Index (PSQI) is an
effective instrument used to measure the quality
and patterns of sleep in various patients [9, 13, 14],
therefore, we chose PSQI to assess the quality of
sleep over the last month in our patients. PSQI has
19 self-rated questions and 5 questions rated by
partner or roommate. Only self-rated questions are
included in the scoring and are used to generate
seven composite scores, each of which gives a score
of 0–3 points. The results give numbers in seven
categories: subjective sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, sleep
disturbances, use of sleeping medication, and day-
time dysfunction. A score of 0 indicates “very good,”
1 indicates “fairly good,” 2 indicates “fairly bad,” and
3 indicates “very bad.” The global score of PSQI is
calculated as the sum of the scores from the seven
categories, with a range of 0–21. A global score
above 7 indicates poor sleep. The PSQI scores from
MHD patients were compared to the results of a
national norm reported by Liu [15].
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4) Quality of Life
The 36-item short-form has been validated, is used
widely across medical disciplines, and can be self-
administered by the patients reliably [3, 16, 17].
The SF-36 was chosen to survey health status in the
301 patients on MHD. It is a generic, multi-purpose,
short-form health survey with only 36 questions,
which measures eight concepts: physical functioning
(PF), role limitations due to physical health (RP),
bodily pain (BP), general health perceptions (GH),
vitality (VT), social functioning (SF), role limitations
due to emotional problems (RE), and general mental
health (MH). Two summary measures of physical
(PCS) and mental (MCS) health are derived from
the eight scales. The SF-36 scores of our patients
were compared to the level of a sociodemographically
equivalent national norm of China [18].
Statistical analysis
Data were transferred by Epi-data3.1 and analyzed with
SPSS13.0 software. Quantitative data was measured by
mean and standard deviation, while qualitative data was
determined by percentage and proportion. Spearman
correlation coefficiency was used to analyze the correl-
ation between quality of sleep and symptom distress, as
well as between quality of life and symptom distress. A
two-sided test was used to examine all data and p < 0.05
was considered statistically significant for all the analyses.
Results
General results
The general information of the patients are shown in
Table 1. A total of 310 copies of questionnaire were
distributed and 301 valid copies were returned. The
valid response rate was 97.1 %. There were 177 male
(58.80 %) and 124 female (41.20 %). The age of the re-
spondents was 53.5 ± 13.9 years. 81.4 % of the patients
received traditional hemodialysis, only 2.3 % were
treated with hemodiafiltration and the other 16.3 % of
them had to use a combination of both methods. 80.4 %
of the patients received dialysis three times per week. The
average dialysis duration was 6.26 ± 5.57 years. The la-
boratory examinations showed that 68.1 % of the patients
had a hemoglobin level lower than our laboratory normal
standard value (Table 2). 78.7 % of the patients had an in-
creased serum phosphorus level and the iPTH level was
elevated in 89.7 % of these patients. Kt/V was above 1.2 in
85.4 % of the patients (Table 2).
Symptoms
The patients in this study had a heavy symptom burden
(Table 3), 14 out of the 30 symptoms were reported in at
least 50 % of the patients. The top three common symp-
toms were dry skin, itching and difficult asleep, which
were reported by 80.4 %, 77.7 % and 76.1 % of the patients,
respectively. The three most severe symptoms were
itching, decreased interest in sex and difficult asleep with
a severity score of 3.41 ± 1.53, 2.83 ± 1.57, 2.70 ± 1.27, re-
spectively (Table 3). Another 10 symptoms were described
as at least “bothering somewhat” (Table 3).







Male 177 58.8 %
Female 124 41.2 %
Age (years) 53.5 ± 13.9
Dialysis Mode
Hemodialysis 245 81.4 %
Hemodiafiltration 7 2.3 %
Combination of both 49 16.3 %
Dialysis frequency
Three times/week 242 80.4 %
Five times/two weeks 19 6.3 %
Twice/week 25 8.3 %









Hemoglobin (g/L) <120 204 68.1 %
120–160 92 30.6 %
>160 4 1.3 %
Red blood cell Count (cell/L) <4 × 10^12 139 46.2 %
4–5.5 × 10^12 92 30.6 %
>5.5 × 10^12 70 23.3 %
Hematocrit <0.420 285 94.7 %
0.420–0.490 13 4.3 %
>0.49 3 1.0 %
Serum phosphorus (mmol/L) <0.97 3 1.0 %
0.97–1.62 61 20.3 %
>1.62 237 78.7 %
Product of Calcium and
phosphorus
<55 110 36.5 %
>55 191 63.5 %
iPTH (pg/mL) <12 5 1.7 %
12–80 26 8.6 %
>80 270 89.7 %
Kt/V ≤1.2 44 14.6 %
>1.2 257 85.4 %
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Quality of sleep
Quality of sleep in our patients was examined using the
PSQI. Our results showed that the score of each of the
eight categories, as well as the global PSQI score (8.5 ±
4.61 vs 3.88 ± 2.52, p < 0.001) of the patients in the current
study, was significantly higher than the national norm [15]
(Table 4), indicating that the patients had poor sleep.
Quality of life
Either symptom burden or poor sleep could impair the
quality of life; therefore, we measured the quality of life
in these MHD patients using the SF-36 questionnaire.
Table 5 displayed the SF-36 scores of our patients, com-
pared to the well-accepted national norm-based scores
in China. The scores of physical component summary
(PCS) and mental component summary (MCS) of the
patients were significantly lower than the national norm
level of China (PCS: 48.42 ± 21.12 vs 77.54 ± 15.96; MCS:
51.64 ± 19.50 vs 71.29 ± 17.86; p < 0.001). In addition,
these patients had a reduced score in each category of
the SF-36, compared to the national norm [18]. Overall,
the patients had impaired quality of life.
Correlation between symptom distress and quality of
sleep and life in MHD patients
The impaired quality of life and poor sleep of the MHD
patients may be associated with high prevalence of
symptoms. To test the hypothesis, Spearman correlation
coefficient was used to analyze the correlation between
symptom distress and quality of sleep as well as quality
of life in these patients. The score of each component of
PSQI and the global score of PSQI were positively corre-
lated with both the presence and the severity of symp-
toms (Table 6) Higher PSQI score, which predicts the
Table 3 The prevalence of symptoms in MHD Patients








Dry skin 242 80.4 (2.79 ± 1.24)
Itching 234 77.7 (3.41 ± 1.53)
Difficulty asleep 229 76.1 (2.70 ± 1.27)
Feel tired or lack of energy 223 74.1 (2.47 ± 1.16)
Trouble falling asleep 206 68.4 (2.57 ± 1.36)
Decrease interest in sex 201 66.8 (2.83 ± 1.57)
Dry mouth 199 66.1 (2.28 ± 1.14)
Difficulty becoming sexually
aroused
195 64.8 (2.79 ± 1.60)
Difficulty concentrating 176 58.5 (2.09 ± 1.12)
Bone or joint pain 173 57.5 (2.24 ± 1.28)
Feeling irritable 173 57.5 (2.09 ± 1.18)
Worrying 172 57.1 (2.10 ± 1.16)
Muscle Soreness 161 53.5 (2.02 ± 1.13)
Cough 154 51.2 (1.89 ± 1.03)
Feeling anxious 152 50.5 (1.96 ± 1.16)
Muscle cramps 145 48.2 (1.78 ± 0.96)
Feeling sad 145 48.2 (1.93 ± 1.18)
Headache 144 47.8 (1.83 ± 1.01)
Lightheadedness or dizziness 143 47.5 (1.74 ± 0.92)
Feeling nervous 139 46.2 (1.86 ± 1.11)
Decreased appetite 130 43.2 (1.72 ± 0.94)
Constipation 128 42.5 (1.82 ± 1.11)
Shortness of breath 122 40.5 (1.71 ± 0.97)
Numbness or tingling in feet 117 38.9 (1.72 ± 1.07)
Nausea 106 35.2 (1.52 ± 0.80)
Restless legs/difficulty keeping
legs still
95 31.6 (1.57 ± 0.97)
Swelling in legs 94 31.2 (1.51 ± 0.86)
Chest pain 87 28.9 (1.49 ± 0.87)
Vomiting 73 24.3 (1.36 ± 0.71)
Diarrhea 70 23.3 (1.38 ± 0.76)
aBased on the five-point Likert scale: 0 “not at all bothersome” to 4 “bothers
very much.”
Table 4 The quality of sleep in MHD patients





Sleep quality 1.46 ± 0.85 0.63 ± 0.68 <0.001
Sleep latency 1.67 ± 1.1 0.70 ± 0.86 <0.001
Sleep duration 1.68 ± 1.19 0.70 ± 0.58 <0.001
Sleep efficiency 0.44 ± 0.91 0.15 ± 0.47 <0.001
Sleep disturbances 1.14 ± 0.61 0.90 ± 0.44 <0.001
Use of sleep medication 0.7 ± 1.16 0.06 ± 0.24 <0.001
Daytime dysfunction 1.4 ± 0.95 0.73 ± 0.83 <0.001
PQSI global score 8.5 ± 4.61 3.88 ± 2.52 <0.001
aData cited from reference [15]
Table 5 The quality of Life in MHD patients





Physical functioning 61.63 ± 29.20 87.92 ± 16.98 <0.001
Role functioning/physical 31.15 ± 39.94 77.5 ± 34.86 <0.001
Body pain 63.62 ± 22.77 82.22 ± 16.98 <0.001
General health 37.30 ± 18.89 62.51 ± 17.88 <0.001
Vitality 59.67 ± 19.86 68.17 ± 17.63 <0.001
Social functioning 60.47 ± 22.51 80.67 ± 19.98 <0.001
Role functioning/emotional 41.97 ± 45.29 67.86 ± 39.44 <0.001
Mental health 57.29 ± 15.98 68.47 ± 16.90 <0.001
Physical component summary 48.42 ± 21.12 77.54 ± 15.96 <0.001
Mental component summary 54.85 ± 20.13 71.29 ± 17.86 <0.001
aData cited from reference [18]
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poorer sleep quality, was associated with more frequent
and worse symptoms. Moreover, a negative correlation
between symptom distress and quality of life was re-
vealed by analysis of the Spearman correlation coeffi-
cient (Table 6). The score of each component of SF-36
and the global score were inversely correlated with the
existence and severity of the symptoms, which suggested
that the quality of life in these MHD patients decreased
with the increase in symptom burden.
Discussion
The present study revealed that the MHD patients from
southern China had a heavy symptom burden. Also, and
the high prevalence of symptoms was correlated to a
significant reduction in quality of life and sleep. The re-
sults of this study suggested that patients on MHD in
the current study struggled with a variety of symptoms
that may have affected patients’ perception of their pos-
ition in life and impair physical, social and emotional
well-being.
Our findings were largely in agreement with others.
Weisbord te. al. carefully examined the association of
symptom burden with quality of life in 162 patients [12].
The authors found that four out of the thirty symptoms
were reported in at least 50 % of the patients, and overall
symptom burden and severity were associated with
impaired quality of life [12]. Using the DSI tool, we mea-
sured the symptom distress in our MHD patients
(Table 3). The patients in our study showed a very simi-
lar spectrum of symptoms as those in Weisbord’s study.
With the exception of bone/joint pain, the other three
most common symptoms reported in MHD patients of
Weisbord’s study, dry skin, feeling tired or lack of energy
and itching, were also among the most prevalent symp-
toms in our study (Table 3). Surprisingly, another 10
symptoms presented in over 50 % patients, and even the
least common symptom, diarrhea, was reported by
23.3 % of our patients (Table 3). Itching was reported by
77.7 % of the patients and was the most severe symp-
toms; moreover, another 12 symptoms were ranked as at
least “bothers somewhat” (Table 3). It appears that the
patients in this study had a heavier symptom burden
than the patients in Weisbord’s study [12]. The differ-
ences in demographics, ethnicity, culture and socioeco-
nomic background may have an influence in answering
the questionnaire, perception and description of the
symptoms. However, investigations on MHD patients,
albeit of a much smaller scale, from other regions of
China disclosed similar pervasiveness and severity of
symptoms as ours [19].
The purpose of this study was not set to examine the
underlying causes for the symptoms. Nevertheless, we
speculated that the high symptom burden reported by
the patients in this study may attribute to inadequate
dialysis. The biochemical measurements of the patients
suggested that the patients might not receive adequate
hemodialysis despite that 85.4 % of them had a Kt/V of
above 1.2, which is an indicator of small molecule clear-
ance (Table 2). The serum phosphorus levels in 78.7 %
of the patients and iPTH levels in 89.7 % of them were
higher than our laboratory normal standard (Table 2).
Furthermore, 68 % of the patients in this study had a
hemoglobin concentration lower than normal which was
also an indicator of inadequate renal replacement therapy
(Table 2). These results indicated that the dialysis treat-
ment might not be enough in terms of relieving symptoms
and removal of phosphates as well as large solutes, such
as iPTH. It is possible that non-compliance to diet might
have contributed to abnormal biochemical measurements,
but we have very clear guidelines for diet control in this
patient population (data not shown). We understand that
it may not be easy to completely follow the strict guide-
lines; however, we believe that majority of these patients
had good compliance to diet control, based on other
hematological measurements, such as serum urea and
creatinine concentrations (data not shown).
Table 6 The correlation of symptom stress with quality of sleep









Physical functioning −0.383* −0.478*
Role functioning/physical −0.326* −0.382*
Body pain −0.438* −0.535*
General health −0.342* −0.444*
Vitality −0.458* −0.525*
Social functioning −0.350* −0.428*
Role functioning/emotional −0.440* −0.492*
Mental health −0.282* −0.311*
Physical component summary −0.486* −0.591*
Mental component summary −0.511* −0.584*
SF-36 global score −0.524* −0.619*
PQSI components
Sleep quality 0.430* 0.517*
Sleep latency 0.242* 0.348*
Sleep duration 0.243* 0.305*
Sleep efficiency 0.224* 0.323*
Sleep disturbances 0.410* 0.507*
Use of sleep medication 0.285* 0.362*
Daytime dysfunction 0.558* 0.633*
PSQI global score 0.485* 0.600*
*p < 0.001
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Symptoms, such as itching, pain, anxiety and worry,
can disturb the patients’ day and night rhythm and cause
severe sleep problems, which further impair their mental
and physical capacity. The high burden of emotional and
physical symptoms was significantly correlated to the
poor sleep of the patients in the present study (Table 6).
The patient with heavier symptom burden generally had
worse sleep quality (Table 6). It has been reported that
the global sleep quality score was a significant independ-
ent predictor of mental and physical health evaluated by
SF-36 in hemodialysis patients even after controlling a
variety of factors [9]. Similarly, our study not only
demonstrated that the MHD patients had reduced life
quality, but also disclosed that the quality of life was cor-
related to the prevalence and severity of symptoms
(Table 6). Patients with more as well as severer symp-
toms reported a poorer quality of life, which was in line
with reports by others [9, 10]. The high prevalence and
severity of symptoms would have a substantial negative
impact on the daily life of patients and could contribute
to the poor sleep and impaired quality of life in patients
on MHD.
Quality of life is an important measurement of clinical
outcomes for patients on hemodialysis [5–7]; specifically,
reduced PCS and MCS scores in MHD patients was as-
sociated with increased risks in hospitalization and mor-
tality, and increase in PCS and MCS scores predicted
better survival [5, 6]. The dialysis clinics in other coun-
tries, such as United States, had already included an
annual measurement of health-related quality of life in
most dialysis patients with the belief that quality of life
monitoring has great potential to improve patient
outcomes, yielding benefits that exceed burdens for
patients and clinics. However, guidelines for adequate
hemodialysis in China are mainly based on biochemical
measurements and a Kt/V of above 1.2. Kt/V is an index
for clearance of small solutes by dialysis. Many studies
have demonstrated that there was no association be-
tween Kt/V and quality of life or sleep [20–22], indicat-
ing that Kt/V may not be an optimal parameter for
evaluating dialysis adequacy in regard to improvements
in quality of sleep or quality of life. Regardless of a Kt/V
of above 1.2 in 85.4 % of these patients, the high perva-
siveness of symptoms as well as increases in serum
iPTH, phosphorus levels and calcium and phosphorus
products suggested that these patients might not receive
enough dialysis treatment. Increase in dialysis dose and
alternate blood purification methods, such as hemofiltra-
tion, hemoperfusion or hemodiafiltration and nocturnal
dialysis, which are able to remove uremic toxins more
efficiently, may be helpful in improving dialysis effective-
ness. Modifications on dialysis regimen have been shown
to improve various domains of health-related quality of
life [23–25]. Thus, our findings supported the necessity
for incorporating evaluation of symptom burden as well
as quality of life among patients on dialysis as guidelines
for measurements of dialysis adequacy.
Our study also suggested that incorporation of DSI
assessment in patient management could provide infor-
mation for diagnosis of underlying pathophysiological
changes and choosing medical treatments of symptoms.
For instances, itching, the worst symptom reported in
this study, could be resulted from a combination of
various factors, such as atrophy of sweat glands, dermal
pathological alterations and secondary to hyperpara-
thyroidism [26]. Medical treatment of itching should
target these possible factors.
Bodily pain and sexual dysfunction can adversely affect
life quality, and depressive symptoms were also associ-
ated with morbidity and mortality of patients with ESRD
and hemodialysis [12, 14, 27]. Medications and interven-
tions specifically relieving or ameliorating these symp-
toms could be useful in improving sleep and satisfaction
with life in these patients.
We recognized that possible limitations to this study
should be addressed. Firstly, the degree that our conclu-
sion can be extrapolated to other areas of China may be
considerably limited. However, our results were similar
to what had been reported in China [19, 28]; in addition,
economy in Guangdong region has been developed bet-
ter than the majority areas of China. Thus, hemodialysis
patients in Guangdong could possibly receive a better
socioeconomic support than many other areas in China
and we speculated that the nationwide quality of life and
clinical outcomes of patients on MHD could be even
worse than the results reported in this study. Secondly,
we may not be able to fully exclude the patient bias. The
patients who were feeling sicker might not be willing to
answer the questionnaire, while it was also possible that
some patients might have reported severer symptoms in
the hopes of obtaining more attention and better treat-
ments from health care givers. Nevertheless, our results
were similar to what had been reported both from China
and other countries [12, 19, 28], we considered that the
patient-bias was minimal. In the end, the quality of life
of the patients in this study was evaluated by the SF-36
instrument, which doesn’t take into account of the specific
concerns of patients with kidney diseases and ESRD who
are treated by dialysis. The effectiveness and reliability of
SF-36 in analyzing quality of life have been validated in
patients with various diseases, including ESRD and
hemodialysis patients [3, 16, 17, 29]. We believe that our
results should be able to suggest that quality of life in
these patients was generally impaired. Future studies util-
izing the Kidney Disease Quality of Life Short Form could
facilitate the diagnosis of particular problems associated
with kidney diseases, and further provide information for
identifying treatments specifically for this population.
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Conclusion
In summary, our results demonstrated that hemodialysis
patients from southern China generally had larger symp-
tom distress and higher prevalence of symptoms, com-
pared to patients from better developed countries. More
importantly, the compromised quality of life and disturbed
sleep in these patients were significantly correlated to the
symptom distress. This study suggests measurements of
the clinical outcomes for hemodialysis patients should in-
clude management of symptoms, morbidity and quality of
life. The ultimate goal of treatments for these patients is
to reduce hospitalization, increase survival and improve
patient self-perceived quality of life.
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